FDA Generic Versus Innovator Study Planned For JAMA

FDA is conducting a study of bioequivalence differences between generic and brand-name drugs, Office of Generic Drugs Director Douglas Sporn told the National Association of Pharmaceutical Manufacturers annual meeting in Puerto Rico Feb. 3.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet